Stock Analysis

L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality

  •  Updated
KOSDAQ:A290650
Source: Shutterstock

L&C Bio Co., Ltd's (KOSDAQ:290650) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that this might be because shareholders have noticed some concerning underlying factors.

View our latest analysis for L&C Bio

earnings-and-revenue-history
KOSDAQ:A290650 Earnings and Revenue History April 1st 2021

How Do Unusual Items Influence Profit?

To properly understand L&C Bio's profit results, we need to consider the ₩5.5b gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that L&C Bio's positive unusual items were quite significant relative to its profit in the year to December 2020. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On L&C Bio's Profit Performance

As we discussed above, we think the significant positive unusual item makes L&C Bio's earnings a poor guide to its underlying profitability. For this reason, we think that L&C Bio's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But at least holders can take some solace from the 5.4% per annum growth in EPS for the last three. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about L&C Bio as a business, it's important to be aware of any risks it's facing. Every company has risks, and we've spotted 1 warning sign for L&C Bio you should know about.

This note has only looked at a single factor that sheds light on the nature of L&C Bio's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

If you’re looking to trade L&C Bio, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Valuation is complex, but we're helping make it simple.

Find out whether L&C Bio is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

About KOSDAQ:A290650

L&C Bio

L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine.

Imperfect balance sheet with poor track record.

Stock Analysis

No articles found